Sean Pitroda to Immunotherapy
This is a "connection" page, showing publications Sean Pitroda has written about Immunotherapy.
Connection Strength
1.518
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
Score: 0.559
-
Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019 08; 20(8):e434-e442.
Score: 0.480
-
Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022 01; 8(1):9-20.
Score: 0.140
-
Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019 09 02; 10(1):3959.
Score: 0.121
-
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. Oncoimmunology. 2023; 12(1):2222560.
Score: 0.039
-
Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):202-213.
Score: 0.037
-
Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654.
Score: 0.037
-
Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy. Neoplasia. 2022 05; 27:100782.
Score: 0.036
-
Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clin Cancer Res. 2021 10 01; 27(19):5188-5194.
Score: 0.035
-
Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
Score: 0.033